{"url_path":"/sec/stro/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1382101/0001193125-26-224065-index.html","accession_number":"0001193125-26-224065","cik":"0001382101","ticker":"STRO","issuer_name":"SUTRO BIOPHARMA, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1382101/0001193125-26-224065-index.html","primary_entity_key":"0001382101","primary_entity_name":"SUTRO BIOPHARMA, INC."},"word_count":95,"has_tables":true,"body_markdown":"Item 9.01. Financial Statements and Exhibits\n\n \n\n(d) Exhibits.\n\nExhibit\nNo.\n\nDescription\n\n \n\n \n\n99.1\n\n[Press release issued by Sutro Biopharma, Inc. regarding its financial results for the quarter ended March 31, 2026, dated May 14, 2026.](stro-ex99_1.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nSutro Biopharma, Inc.\n\nDate: May 14, 2026\n\nBy:\n\n/s/ Gregory Chow\n\nGregory Chow\n\nChief Financial Officer"}